The stock is just fine where it's at. You appear to be stuck in this whole 'year low', '2013 low' mentality. Its a completely wrong methodology to judge this particular stock. Especially being we are up over 300% since last december.
The fact is, though, until EPGL proves they belong at these levels, liquidity will not increase and pps won't increase a s result. Simple as that. Merely having the company think they are undervalued doesn't cut it.
I love that they think that, though. I want my company to be cocky and believe they are undervalued. What good company on the market doesn't? And I believe its warranted.
The big, giant question, is....WHAT CONSTITUTES AS PROOF to the main market...that this start up bio tech penny stock on the Pink Sheets belongs in the cents? I believe that having a 7 billion dollar, publicly traded company, validate your product and technology will be the prime proof that we need. Couple that with the SEC registration which will bring in investment funds, etc, etc, etc, we will see a nice bump in liquidity which will take the price up. If I'm wrong, well, I'm wrong.
If indeed, that is the proof that is needed, which i believe it is, it will go up very, very quickly. Biotechs/biopharms are all about timing and patience. If your timing sucks and you have no patience, well, you're screwed. Of those waiting for the news to hit before they get in....well, 10% will be able to get in at these levels, 30% will get in the high .02's and 60% won't get in at all.
The whole reason people do these start up bio techs are for the huge, instant increases that happen very quickly. And it never, ever, ever, ever happens when expected.
If I am correct, when EPGL PR's the deal, everybody over the last year that has said to get in at these levels...the .015-.025 range will be proven to have been exactly correct, as this will be the low end of the PPS range when liquidity increases.
Market Data 
Markets 
